Longevity Technology Unlocked — Muse Cells Deep Dive
Guests & Context
Dr. Dominic Ducher (CEO) and Dr. Jeffrey Wagner (CMO) of Musel Innovations, which works with Dazawa Muse Cells — a naturally occurring stem cell subpopulation discovered by Professor Mari Dazawa. The company focuses on translating this platform into therapeutic and aesthetic applications.
Personal Longevity Practices (Opening Question)
Dominic practices plasmapheresis every six months using an Enospheresis device for blood cleansing — something he considers scientifically compelling and personally impactful.
Jeffrey takes a more naturalistic approach — sunlight, circadian rhythm alignment, walking, and exercise as the foundation. He adds a philosophical note: learning about cell biology taught him the importance of goal-directedness, and he considers setting goals one of the most underrated longevity strategies.
Why Stem Cell Therapies Have Underdelivered
Jeffrey frames this honestly. The stem cell field suffered from overconfidence — the biological complexity turned out to be far greater than anticipated, similar to what’s happening with gene therapies. He identifies several compounding factors:
- Forcing cells to do what we want is harder than expected
- Clinical trials are enormously difficult to establish, fund, and complete
- Working with living cells adds layers of complexity that don’t exist with conventional pharmaceuticals
- These challenges often go unspoken when the public asks “where are the results?”
The Wine Vintage Analogy
Dominic introduces this analogy to explain why biologics development is fundamentally different from traditional drug development. A pharmaceutical drug is like baking cookies — same recipe, consistent output. A cell product is more like wine — the grape variety, the region, the vintner’s hand, and the year all matter. The key variables are:
- Tissue source quality
- Manufacturing process control
- Facility standards
- Expertise of the people involved
He notes that regulatory frameworks were built around the “cookie cutter” pharmaceutical model and struggle to accommodate biologics. He expresses enthusiasm for Florida’s approach, which shifts regulatory focus to the quality of the manufacturing process itself as the primary determinant of whether a product should be in circulation — rather than forcing biologics through frameworks designed for small molecules.
What Muse Cells Are
Dominic uses the metaphor of an elite squad within a larger repair army. All stem cells serve as the body’s repair troops, but Muse cells are the exceptional subpopulation — representing only a fraction of the total stem cell population. The therapeutic product is a purified, enriched preparation that is more than 70% characterized Muse cells — essentially concentrating those super-troopers.
The Three Pillars in Detail
1. Pluripotency
Standard MSCs (mesenchymal stem cells) are multipotent — they can differentiate within a limited niche. Fat-derived stem cells can become fat, cartilage, or bone. Muse cells are pluripotent, meaning they can become any tissue across all three germ layers. Jeffrey explains the mechanism in detail:
- Upon arriving at a damage site, Muse cells perform a kind of diagnostic assessment
- Cells that are salvageable can be repaired through signaling proteins or mitochondrial donation
- Cells too far gone are phagocytosed — the Muse cell consumes the dying cell’s genetic material
- By reading which genes were being expressed (the epigenetic signature), the Muse cell determines what cell type that was
- It then differentiates into that exact cell type to replace it
This has been demonstrated in culture — Muse cells arriving at cardiac tissue, consuming dying cardiomyocytes, and then beginning to express cardiac myocyte genetic patterns confirmed by fluorescent dye imaging. Jeffrey calls this “choosing a career after arriving at the job site.”
2. Homing
Standard MSCs home very poorly. Their signaling via the CXCR4/SDF-1 axis is imprecise and unreliable after IV infusion. Muse cells, by contrast, follow sphingosine-1-phosphate (S1P) gradients — the same chemokine signaling pathway used by monocytes and macrophages that are drawn to tissue debris. Dominic describes this as the cell being able to “smell the damage,” or as Professor Dazawa puts it, having a built-in GPS system.
Travis raises an interesting question here — whether these distress signals could also come from senescent cells, potentially allowing Muse cells to clear senescent burden. Neither executive could confirm this with data, but Dominic acknowledges it’s scientifically plausible if the SASP (senescent secretory signaling) includes S1P components, and notes it would be a worthwhile research avenue for Professor Dazawa.
3. Immune Tolerance
Jeffrey considers this the most important differentiator, and the one that unlocks everything else. Traditional MSCs are eventually rejected by the recipient’s immune system — a fundamental ceiling on their therapeutic utility. Muse cells express low immunogenicity and carry what Jeffrey calls a “universal passport.”
The biological analogy he draws is to HLA-G, a protein expressed by placental tissue — which is technically foreign genetic material inside the mother’s body — that prevents immune rejection. Muse cells use a similar mechanism to signal to the host immune system that they are allies. This makes them suitable for off-the-shelf allogeneic use — donor cells can be prepared, stored, and administered without needing immune matching or suppression.
Jeffrey speculates this could have implications far beyond cell therapy — potentially for transplantation medicine more broadly. He describes Muse cells as being able to speak a “universal language” while transiting between what are effectively different immunological ecosystems (organs/tissues).
The combination of all three pillars means Muse cells can be administered as a ready-made IV product, find the site of injury autonomously, know what to do when they arrive, and be accepted by the host — making them, in Dominic’s words, “the only truly system-wide regenerative agent in the biologic space.”
Human Trial Results
Acute Myocardial Infarction (Phase 1)
- 3 patients enrolled, all with left ventricular ejection fraction below 45%
- IV administration of 15 million Muse cells
- At 12 weeks: ejection fraction increased by more than 10% in all patients
- Wall motion scores also improved, suggesting genuine cardiac muscle regeneration
-
Zero side effects — primary goal of safety was met, with encouraging efficacy signals
Subacute Ischemic Stroke (Randomized Placebo-Controlled)
- 35 patients enrolled, treated in the subacute phase after stroke
- Two-arm study design
-
40% response rate in the Muse cell group vs. 10% in placebo
- Again primarily a safety trial, but the efficacy signal was considered highly encouraging
The transcript cuts off as Jeffrey begins elaborating further on the stroke study.
Overall Framing
The executives position Muse cells not as a marginal improvement on existing MSC approaches but as a mechanistically distinct platform — one that works with the body’s own repair logic rather than trying to force an outcome. The regulatory and manufacturing challenges are real, but they frame them as solvable through process-focused oversight and rigorous manufacturing standards.
